HomeCompareSNIPF vs PFE

SNIPF vs PFE: Dividend Comparison 2026

SNIPF yields 5405.41% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNIPF wins by $132781606524346.58M in total portfolio value
10 years
SNIPF
SNIPF
● Live price
5405.41%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$132781606524346.63M
Annual income
$128,119,059,269,614,270,000.00
Full SNIPF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SNIPF vs PFE

📍 SNIPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNIPFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNIPF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNIPF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNIPF
Annual income on $10K today (after 15% tax)
$459,459.46/yr
After 10yr DRIP, annual income (after tax)
$108,901,200,379,172,130,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SNIPF beats the other by $108,901,200,379,172,110,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNIPF + PFE for your $10,000?

SNIPF: 50%PFE: 50%
100% PFE50/50100% SNIPF
Portfolio after 10yr
$66390803262173.34M
Annual income
$64,059,529,634,807,150,000.00/yr
Blended yield
96.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SNIPF
No analyst data
Altman Z
-1.8
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNIPF buys
0
PFE buys
0
No recent congressional trades found for SNIPF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNIPFPFE
Forward yield5405.41%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$132781606524346.63M$49.6K
Annual income after 10y$128,119,059,269,614,270,000.00$26,258.71
Total dividends collected$132466925838827.91M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SNIPF vs PFE ($10,000, DRIP)

YearSNIPF PortfolioSNIPF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$551,241$540,540.54$9,153$693.39+$542.1KSNIPF
2$28,437,291$27,847,463.53$8,593$849.25+$28.43MSNIPF
3$1,373,034,993$1,342,607,092.16$8,336$1,066.78+$1373.03MSNIPF
4$62,053,231,229$60,584,083,785.63$8,437$1,384.80+$62053.22MSNIPF
5$2,625,321,984,246$2,558,925,026,831.29$9,013$1,875.40+$2625321.98MSNIPF
6$103,988,461,629,195$101,179,367,106,051.90$10,306$2,680.72+$103988461.62MSNIPF
7$3,856,775,911,957,070$3,745,508,258,013,831.00$12,820$4,101.38+$3856775911.94MSNIPF
8$133,954,112,586,765,570$129,827,362,360,971,500.00$17,673$6,826.70+$133954112586.75MSNIPF
9$4,357,520,798,815,286,000$4,214,189,898,347,446,300.00$27,543$12,591.86+$4357520798815.26MSNIPF
10$132,781,606,524,346,630,000$128,119,059,269,614,270,000.00$49,560$26,258.71+$132781606524346.58MSNIPF

SNIPF vs PFE: Complete Analysis 2026

SNIPFStock

Snipp Interactive Inc., a loyalty and promotions company, focuses on developing marketing engagement platforms in the United States, Canada, Ireland, and internationally. Its solutions include shopper marketing promotions, loyalty, rewards, rebates, and receipt processing. The company also engages in designing, executing, and promoting marketing programs. Snipp Interactive Inc. offers SnippCheck, a mobile receipt processing solution that allows brands to execute purchase-based promotions and loyalty programs; SnippWin, a promotion and sweepstakes platform provides various promotions from contests and simple sweepstakes to instant win programs and tiered, multi-level games; and SnippLoyalty, a solution that allows clients to deploy from simple punch-card programs to points-based loyalty programs with rewards stores. It also provides SnippRewards, a rewards platform that offers various rewards, including movie tickets, PayPal, and other money back mechanisms; and SnippInsights Data Analytics, a tool that collects and unifies data across all the programs that clients run on the snipp platform. In addition, the company offers SnippRebates, a SaaS platform that allows brands to set up and manage single-instance or cross-portfolio rebates; and SnippRx, a solution that allows medical practitioners to distribute incentives like coupons and pay-no-more cards direct to patients via text or email. It serves advertising agencies, brands and related marketing, and promotions agencies. Snipp Interactive Inc. was founded in 2007 and is headquartered in Vancouver, Canada.

Full SNIPF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SNIPF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNIPF vs SCHDSNIPF vs JEPISNIPF vs OSNIPF vs KOSNIPF vs MAINSNIPF vs JNJSNIPF vs MRKSNIPF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.